ALK and non-small cell lung carcinoma: This contrasts with the previous brigatinib exposure‐response analysis of patients with refractory ALK+ NSCLC in the phase I/II and ALTA trials showing that increasing daily time‐varying brigatinib AUC was a significant predictor of improved PFS.13, 19